CN112971146B - Composition and food for improving bone health and application - Google Patents
Composition and food for improving bone health and application Download PDFInfo
- Publication number
- CN112971146B CN112971146B CN202110237626.4A CN202110237626A CN112971146B CN 112971146 B CN112971146 B CN 112971146B CN 202110237626 A CN202110237626 A CN 202110237626A CN 112971146 B CN112971146 B CN 112971146B
- Authority
- CN
- China
- Prior art keywords
- calcium
- bone
- composition
- polydextrose
- vitamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 30
- 235000013305 food Nutrition 0.000 title claims abstract description 23
- 230000037180 bone health Effects 0.000 title claims abstract description 17
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims abstract description 98
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 89
- 239000011575 calcium Substances 0.000 claims abstract description 88
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 88
- 229920001100 Polydextrose Polymers 0.000 claims abstract description 49
- 229940035035 polydextrose Drugs 0.000 claims abstract description 49
- 235000013856 polydextrose Nutrition 0.000 claims abstract description 49
- 239000001259 polydextrose Substances 0.000 claims abstract description 49
- 241001465754 Metazoa Species 0.000 claims abstract description 48
- 150000003271 galactooligosaccharides Chemical class 0.000 claims abstract description 48
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims abstract description 47
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 42
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 35
- 229930003316 Vitamin D Natural products 0.000 claims abstract description 27
- 235000019166 vitamin D Nutrition 0.000 claims abstract description 27
- 239000011710 vitamin D Substances 0.000 claims abstract description 27
- 150000003710 vitamin D derivatives Chemical class 0.000 claims abstract description 27
- 229940046008 vitamin d Drugs 0.000 claims abstract description 27
- 230000012010 growth Effects 0.000 claims abstract description 25
- 230000037182 bone density Effects 0.000 claims abstract description 16
- 235000013406 prebiotics Nutrition 0.000 claims abstract description 15
- 229940069978 calcium supplement Drugs 0.000 claims abstract description 6
- 239000002994 raw material Substances 0.000 claims abstract description 4
- 235000016709 nutrition Nutrition 0.000 claims description 9
- 238000000926 separation method Methods 0.000 claims description 5
- 230000003698 anagen phase Effects 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 3
- 235000013365 dairy product Nutrition 0.000 claims description 3
- 235000013402 health food Nutrition 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 3
- 238000006116 polymerization reaction Methods 0.000 claims description 3
- 235000011888 snacks Nutrition 0.000 claims description 3
- 230000002950 deficient Effects 0.000 claims 4
- 230000000694 effects Effects 0.000 abstract description 13
- 229960005069 calcium Drugs 0.000 description 77
- 241000700159 Rattus Species 0.000 description 17
- 210000000689 upper leg Anatomy 0.000 description 16
- 239000011647 vitamin D3 Substances 0.000 description 9
- 235000005282 vitamin D3 Nutrition 0.000 description 8
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 8
- 229940021056 vitamin d3 Drugs 0.000 description 8
- 238000010603 microCT Methods 0.000 description 5
- 239000008267 milk Substances 0.000 description 5
- 235000013336 milk Nutrition 0.000 description 5
- 210000004080 milk Anatomy 0.000 description 5
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 230000037406 food intake Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 239000001736 Calcium glycerylphosphate Substances 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 2
- 229960005147 calcium acetate Drugs 0.000 description 2
- 235000011092 calcium acetate Nutrition 0.000 description 2
- 239000001639 calcium acetate Substances 0.000 description 2
- 235000010376 calcium ascorbate Nutrition 0.000 description 2
- 229940047036 calcium ascorbate Drugs 0.000 description 2
- 239000011692 calcium ascorbate Substances 0.000 description 2
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 description 2
- 108010033929 calcium caseinate Proteins 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 229960002713 calcium chloride Drugs 0.000 description 2
- 229940092124 calcium citrate malate Drugs 0.000 description 2
- 229940062672 calcium dihydrogen phosphate Drugs 0.000 description 2
- 239000004227 calcium gluconate Substances 0.000 description 2
- 229960004494 calcium gluconate Drugs 0.000 description 2
- 235000013927 calcium gluconate Nutrition 0.000 description 2
- 229940095618 calcium glycerophosphate Drugs 0.000 description 2
- UHHRFSOMMCWGSO-UHFFFAOYSA-L calcium glycerophosphate Chemical compound [Ca+2].OCC(CO)OP([O-])([O-])=O UHHRFSOMMCWGSO-UHFFFAOYSA-L 0.000 description 2
- 235000019299 calcium glycerylphosphate Nutrition 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 2
- 239000001527 calcium lactate Substances 0.000 description 2
- 229960002401 calcium lactate Drugs 0.000 description 2
- 235000011086 calcium lactate Nutrition 0.000 description 2
- 239000001362 calcium malate Substances 0.000 description 2
- OLOZVPHKXALCRI-UHFFFAOYSA-L calcium malate Chemical compound [Ca+2].[O-]C(=O)C(O)CC([O-])=O OLOZVPHKXALCRI-UHFFFAOYSA-L 0.000 description 2
- 229940016114 calcium malate Drugs 0.000 description 2
- 235000011038 calcium malates Nutrition 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 229940095672 calcium sulfate Drugs 0.000 description 2
- 235000011132 calcium sulphate Nutrition 0.000 description 2
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 description 2
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 2
- MPCMQXRREZMSPJ-UHFFFAOYSA-L calcium;2-hydroxybutanedioate;2-hydroxypropane-1,2,3-tricarboxylic acid;pentahydrate Chemical compound O.O.O.O.O.[Ca+2].[O-]C(=O)C(O)CC([O-])=O.OC(=O)CC(O)(C(O)=O)CC(O)=O MPCMQXRREZMSPJ-UHFFFAOYSA-L 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 235000019691 monocalcium phosphate Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000004380 ashing Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000010000 carbonizing Methods 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000013170 computed tomography imaging Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 235000008242 dietary patterns Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- FYDKNKUEBJQCCN-UHFFFAOYSA-N lanthanum(3+);trinitrate Chemical compound [La+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O FYDKNKUEBJQCCN-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1522—Inorganic additives, e.g. minerals, trace elements; Chlorination or fluoridation of milk; Organic salts or complexes of metals other than natrium or kalium; Calcium enrichment of milk
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/156—Flavoured milk preparations ; Addition of fruits, vegetables, sugars, sugar alcohols or sweeteners
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/158—Milk preparations; Milk powder or milk powder preparations containing additives containing vitamins or antibiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/174—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
- A23K20/24—Compounds of alkaline earth metals, e.g. magnesium
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention provides a composition for improving bone health, food and application. The composition comprises the following raw material components: the calcium supplement comprises a calcium source, vitamin D and prebiotics, wherein the prebiotics comprise polydextrose and galactooligosaccharides, and the weight ratio of the polydextrose to the galactooligosaccharides is (1-15) to 1. The composition realizes the technical effects of obvious gradual synergy in the aspects of improving the bone density, the bone calcium content and the bone microstructure of animals with insufficient calcium intake in the growth period and other growth stages.
Description
Technical Field
The invention belongs to the technical field of nutritional supplements, and particularly relates to a composition for improving bone health, food and application.
Background
The effect of calcium and vitamin D on promoting bone health is brought into the national GB28050 food safety standard, and the calcium and vitamin D are bone-strengthening elements with sufficient evidence, and the further remarkable improvement effect on the basis of calcium and vitamin D is very difficult to achieve. At present, the situation that the intake of calcium and vitamin D is seriously insufficient in the dietary pattern of children in China exists. In addition, the average calcium intake of other people with calcium malnutrition, such as middle-aged and old people in 50-64 years and 65 years in China is 415mg and 409mg, and the RNI value of calcium of people in the age group is 1000mg, which means that the calcium intake only reaches about 1/3 of the required amount, namely, the calcium intake is seriously insufficient. Therefore, there is a need to develop a new product capable of significantly improving bone health.
Disclosure of Invention
The invention aims to provide a composition for improving bone health, which realizes the technical effects of remarkably increasing the bone density, the bone calcium content and the bone microstructure of animals with insufficient calcium intake in growth stages and other growth stages.
It is a further object of the present invention to provide a food product comprising the above composition.
It is another object of the present invention to provide the use of the above composition or food product for improving one or more of bone density, bone calcium content and bone microstructure in an animal.
According to one aspect of the present invention, there is provided a composition for improving bone health, the composition comprising the raw material components: the calcium supplement comprises a calcium source, vitamin D and prebiotics, wherein the prebiotics comprise polydextrose and galactooligosaccharides, and the polydextrose and the galactooligosaccharides are in a weight ratio of (1-15): 1.
according to one aspect of the invention, the weight ratio of the polydextrose to the galactooligosaccharide is (3-6): 1.
preferably, the composition comprises the following nutritional ingredients in parts by weight: 12-66 ten thousand parts of calcium, 1-7 parts of vitamin D, 266-2240 ten thousand parts of polydextrose and 67-560 ten thousand parts of galacto-oligosaccharide.
Preferably, the calcium source comprises calcium acetate, calcium caseinate, calcium chloride, calcium citrate malate, calcium gluconate, calcium lactate, calcium malate, calcium hydrogen phosphate, calcium dihydrogen phosphate, calcium sulfate, calcium ascorbate, calcium glycerophosphate, and milk calcium.
Preferably, the polydextrose meets the national food safety standard GB 25541-2010. Wherein the average polymerization degree of the polydextrose is 8-16, and the purity is more than 90%. The galacto-oligosaccharides comprise galacto-oligosaccharides to galacto-octaoligosaccharides with a purity > 57% on a dry basis.
According to one aspect of the present invention, there is provided a food product comprising the above composition.
Preferably, the food is selected from at least one of dairy, health food and snack food.
According to another aspect of the present invention there is provided the use of a composition as described above, or a food product comprising a composition as described above, for improving one or more of bone density, bone calcium content and bone microstructure in an animal.
Preferably, the bone microstructure is selected from at least one of trabecular number, trabecular separation, and bone volume fraction.
Preferably, the animal is selected from a growth-stage animal and an animal with insufficient calcium intake during other growth stages than the growth stage; preferably, the animal is a mammal.
Preferably, the growth-stage animal is a growth-stage child; the animals with insufficient calcium intake in other growth stages except the growth stage are human with insufficient calcium intake, preferably middle aged and elderly people with insufficient calcium intake.
The composition provided by the invention comprises the following components: the contents and proportions of calcium, vitamin D, Polydextrose (PDX) and galacto-oligosaccharide (GOX) and the components (calcium content, vitamin content, total PDX + GOS and ratio of polydextrose and galacto-oligosaccharide in PDX + GOS) achieve unexpected health effects, such as increasing bone density, increasing bone calcium content, improving bone microstructure (increasing number of trabeculae, decreasing trabeculae separation, increasing bone volume fraction) in animals in the growth phase and in other growth phases than the growth phase, which are not calcium-ingested.
Drawings
FIG. 1 is a schematic illustration of bone density imaging of rats in example 1 of the present invention;
FIG. 2 is a representative MiCro-CT image of the distal femur cross-section of each group of rats according to example 1 of the present invention.
Detailed Description
Technical features, objects and advantages of the present invention will be more clearly understood and appreciated by those skilled in the art. It should be understood that the following detailed description is merely exemplary, and the technical solution of the present invention is not limited to the specific embodiments listed below.
The invention provides a composition for improving bone health, which comprises the following raw material components: a calcium source, vitamin D and prebiotics. Wherein the prebiotics comprise polydextrose and galactooligosaccharides, and the weight ratio of the polydextrose to the galactooligosaccharides is (1-15) to 1, preferably (3-6) to 1, and more preferably 4 to 1 based on the contained effective substances.
The calcium source comprises calcium acetate, calcium caseinate, calcium chloride, calcium citrate malate, calcium gluconate, calcium lactate, calcium malate, calcium hydrogen phosphate, calcium dihydrogen phosphate, calcium sulfate, calcium ascorbate, calcium glycerophosphate, and milk calcium.
The polydextrose meets the national food safety standard GB 25541-2010. Wherein the average polymerization degree of the polydextrose is 8-16, and the purity is more than 90%. The galacto-oligosaccharides comprise galacto-oligosaccharides to galacto-octaoligosaccharides with a purity > 57% on a dry basis.
According to a particular embodiment, the composition comprises the following nutritional ingredients in parts by weight: 12-66 ten thousand parts of calcium, 1-7 parts of vitamin D, 266-2240 ten thousand parts of polydextrose and 67-560 ten thousand parts of galacto-oligosaccharide.
The invention also provides a food containing the composition. The above components are mixed and applied to various foods such as dairy food, health food and snack food. In particular to liquid milk, modified milk, yoghourt, cheese, milk powder, solid beverage, convenient food, candy and health care products, thereby realizing the technical effect of improving the bone health of Chinese children and people with insufficient calcium intake.
The invention also provides the use of the above composition or a food product comprising the above composition to improve one or more of bone density, bone calcium content and bone microstructure in an animal.
The bone microstructure is selected from at least one of the number of trabeculae, trabecular resolution, and bone volume fraction.
The animals are selected from growth stage animals and animals with insufficient calcium intake in growth stages other than growth stage; preferably, the animal is a mammal.
The growth-stage animals are growth-stage children; the animals with insufficient calcium intake in other growth stages except the growth stage are human with insufficient calcium intake, preferably middle aged and elderly people with insufficient calcium intake.
In summary, the composition provided by the invention has the following advantages:
the components of the composition are as follows: the effect of the calcium + vitamin D + polydextrose + galacto-oligosaccharide combination (polydextrose: galacto-oligosaccharide is 4: 1) applied to animals in growth period is obviously better than that of the higher-dose calcium group, the same-dose calcium + vitamin D group and the other-proportion calcium + vitamin D + PDX + GOS combination (polydextrose: galacto-oligosaccharide is 1: 1) group, and the effects are embodied in that the content of bone calcium is increased, the bone density is increased, the number of bone trabeculae is increased, the separation degree of the bone trabeculae is reduced and the bone volume fraction is increased.
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is further described in detail with reference to the following embodiments.
The methods used in the following examples are conventional methods unless otherwise specified, and the reagents used are commercially available reagents unless otherwise specified.
Chinese children aged 3-6, 7-9 and 10-13 years have calcium intake of only 318mg, 334mg and 390mg on average, and recommended intake (RNI) values of 800mg, 1000mg and 1200mg respectively. Therefore, the invention constructs a growth-period animal model with the calcium intake only accounting for the recommended amount of 1/3, the model is fitted with the calcium nutrition condition of Chinese children, the growth period from 3 to 12 years old is represented by feeding the animal with low-calcium feed for 3 months, and the model animal shows the negative effects on the bone health condition under the condition of low calcium, including low bone calcium content, low bone density, low bone number, reduced trabecular bone number and increased trabecular bone spacing.
The invention provides the effect of improving the bone health of the animals in the growth period under the condition of low calcium nutrition by the high calcium group, and the dosage of the calcium in the high calcium group is supplemented to the recommended ideal dosage of the animals in the growth period.
The invention provides the effect of calcium and vitamin D on improving the bone health of animals in a growth period under the condition of low-calcium nutrition, the dosage of calcium is 3/4 of a high-calcium group after the calcium is supplemented, and the dosage of the vitamin D is 1.48 times of that of the low-calcium group and the high-calcium group.
The invention provides a calcium + vitamin D + PDX + GOS combination (polydextrose and galacto-oligosaccharide are 1: 1) for improving the bone health of animals in a growth period under a low-calcium nutritional condition, the calcium dosage after the calcium supplement is 3/4 of a high-calcium group, the vitamin D dosage is 1.5 times of that of a low-calcium group and that of a high-calcium group, the weight ratio of polydextrose to galacto-oligosaccharide in the PDX + GOS combination is 1: 1, and the dosage of PDX + GOS for children is 0.3-0.78g/kg.
The invention provides a calcium + vitamin D + PDX + GOS combination (polydextrose: galacto-oligosaccharide is 4: 1) for improving the bone health of animals in a growth period under a low-calcium nutritional condition, the calcium dosage after the calcium supplement is 3/4 of a high-calcium group, the vitamin D dosage is 1.5 times of that of a low-calcium group and that of a high-calcium group, the weight ratio of polydextrose to galacto-oligosaccharide in the PDX + GOS combination is 4: 1, and the dosage of PDX + GOS for children is 0.3-0.78g/kg.
Through comparison of the groups, the calcium + vitamin D + PDX + GOS combination (polydextrose: galactooligosaccharide is 4: 1) is obviously superior to the high-calcium group, the calcium + vitamin D group and the calcium + vitamin D + PDX + GOS combination (polydextrose: galactooligosaccharide is 1: 1) group in the aspects of improving bone calcium content, improving bone density, improving the number of bone trabeculae, reducing the space between the bone trabeculae and increasing bone volume fraction.
Examples
Example 1
Test animals and groups:
SPF-grade weaning SD rats 144 male, weighing 45-65 g, purchased from Beijing Wittingle laboratory animal technology Limited, animal qualification number SCXK (Jing) 2016-. The animals are raised in the barrier level animal house of the national institutes of public health of western Sichuan university, the qualification number SYXK (Sichuan) 2018-. During feeding, the animals are ensured to drink water freely and eat fully, and the drinking water is sterilized pure water. The rats are raised in cages with stainless steel wire at the bottom, the animal rooms are kept in quiet, clean, ventilated and proper illumination states, the temperature is 20-26 ℃, the humidity is 40% -70%, and the light and shade alternating period is 12 h.
The rats were fed with AIN-93G standard feed (Nantong Denofil feed science and technology Co., Ltd., production license number: Su-sho ((2019) 06092)) for 2 weeks, and the rats were randomly divided into 5 groups of 12 animals each with calcium and vitamin D3The administration of galacto-oligosaccharides (GOS) and Polydextrose (PDX) was performed in a mixed feeding mode, the experimental groups are shown in table 1, and the feed formula of each group is shown in table 2. All the feeding treatments were carried out continuously for 93 days after the animals were acclimatized, and the animals were sacrificed and examined for each index on the 93 th day of the experiment.
TABLE 1
Note: each component is calculated by weight of each component purity, and 1 mu g of vitamin D3 is 40IU of vitamin D3.
TABLE 2
Note: the weight of vitamin D3 in Table 2 is based on the weight of the material, and the purity of vitamin D3 in the material is 0.25%.
The conversion manner between the daily intake and the parts by weight of each component is as follows:
1 part by weight is 0.78 ug/day intake, and specifically, the daily intake of each component is as follows:
(1) in example 1, the low calcium group was 1/3 normal calcium group, calcium nutrition status was fitted to children aged 3-12 years in China, and calcium supplementation in the intervention group was 3/4 supplemented to the normal requirement, which achieved an effect beyond the expectation. The daily calcium supplement amount is 282-510mg/d calculated by children of 3-12 years old, and the calcium range is 1-3 times/day: 94mg-510 mg/d. The value is calculated by pure calcium, if the calcium sources are different, the calculation is needed according to the purity and the calcium content of the calcium sources, and the invention does not limit the calcium sources, so the protection is only carried out by the pure calcium.
(2) Vitamin D3 was supplemented in example 1 in an amount 1.48 times the dietary intake. The intake of vitamin D3 for children of 3-6, 7-9, and 10-12 years old is 5.24ug, 4.89ug, and 5.85 ug. The supplement amount of vitamin D3 is 2.35-5ug/D per day for children of 3-12 years, and the vitamin D3 is in the range of 1-3 times per day: 0.78-5 ug/d.
(3) The human ingestion dose of prebiotics (PDX + GOS) was 0.52g/kg.bw, calculated from the body weight and ingestion amount of rats in example 1. The prebiotics dosage is set to be 5g/100g of diet at the initial stage of the experiment, the diarrhea condition of the rat occurs, so that 1/3 prebiotics dosage is adjusted in the feed after the diarrhea is found at 0.52g/kg.bw, and the prebiotics dosage protection range is 0.3-0.78g/kg.bw according to the conversion of the weight and the food intake of the rat in the growth process. The weight average range of Chinese children of 3-12 years old is about 15-42kg, so the preferable dosage of the prebiotics is as follows: 7.8g-21.8g/d, and the total dosage of the prebiotics is 2.6g-21.8g/d calculated by 1-3 times/day, wherein the weight ratio of PDX to GOS is 4: 1. It is to be noted that prebiotic dosages are calculated as pure PDX and GOS.
Experimental methods
Animal treatment and sample collection
After the last gavage, the rats were fasted for 16h and water was freely available. After anesthetization, the abdominal veins were bled. The rats were sacrificed by cervical dislocation. The blood sample is centrifuged at 3500r/min for 10min at 4 ℃ to separate serum, and then supernatant is extracted. Serum was stored at-80 ℃ and removed when tested.
After the rats were sacrificed, bilateral femurs were separated, muscles and soft tissues attached to the bone surfaces were removed, and bilateral femurs were exfoliated. The left femur was oven dried in a 105 ℃ oven. The right femur was fixed with 4% paraformaldehyde for 36h, then soaked in 70% alcohol and stored in a refrigerator at 4 ℃ until CT scan.
Determination of femur weight, femur length, bone calcium and bone Density
Femoral weight and femoral length determination
After the left femur was dried in an oven at 105 ℃ to constant weight, the dry weight of the femur was recorded and the length of the femur was measured.
Bone calcium assay
And (3) placing the left femur dried to constant weight in a crucible, heating with soft fire, carbonizing until no smoke exists, transferring to a muffle furnace, and ashing for 3-4 h at 550 ℃. Cooling, taking out, digesting with concentrated nitric acid, fixing the volume to 25mL, taking 40uL to 10mL of colorimetric tube, adding 1mL of 20% lanthanum nitrate solution, fixing the volume to 10mL, shaking up, and measuring by using a flame atomic absorption spectrometer.
Bone Density determination
The bone density of the middle end of each rat femur was measured by a German Bruker DXS PRO type small animal full-automatic high resolution X-ray machine for the rat right femur after Micro-CT scanning, 10 rat femurs were imaged at the same time each time, the pixel resolution was 10 μm, the X-ray lamp voltage was 45kVp, and the exposure time was set to 1 min. The scanning results are shown in fig. 1.
Micro-CT detection
The rat right femur was scanned using a small animal living Micro-CT imaging system from PerkinElmer, usa. And analyzing by adopting Quantum GX micro CT Imaging System software. The scan parameters are set as follows: the field of view was set at 36mm, voxel 72 μm, energy 80kV, intensity 100 μ A, scan time 14 min. After three-dimensional reconstruction of scanning data, 512 pictures with different cross sections are obtained by scanning the same sample, and a region of interest (ROI) is set to be 50 pictures from 0.5mm below a growth layer). And (4) reconstructing the scanning data by using software and then analyzing parameters. The bone density was corrected using a resin-embedded hydroxyapatite solid calibration model from PerkinElmer, and the cortical, cancellous, and all bone densities in the ROI were calculated separately. Other analysis parameters include bone volume fraction (BV/TV), trabecular thickness (tb.th), trabecular number (tb.n), and trabecular separation (tb.sp).
Data processing and result determination
All data are expressed as Mean standard deviation (Mean ± SD). One-way anova was performed using SPSS 26.0 statistical software. Before analysis, the homogeneity of variance is tested, and the F value is calculated. If the F value is less than F0.05 and P is more than 0.05, the mean difference of each group is not statistically significant; if the F value is more than F0.05 and P is less than 0.05, the difference between the mean values of all groups is statistically significant. Mean pairwise comparisons between multiple experimental and control groups were analyzed using LSD except for Dunnett-t for body weight.
Results of the experiment
FIG. 2 shows representative images of cross-sectional Micro-CT of the distal femur of various groups of rats; table 3 shows the Micro-CT scan results for each set of femoral microstructures; table 4 shows the effect of femoral normative index (Mean + SD) for each subject. The white mesh portion below the tibial epiphyseal line in fig. 2 is the trabecular bone. The low calcium group, group 1, had the least number of trabeculae, and was the most sparse, with a wider trabecular spacing. The trabeculae of the normal group (2) and each intervention group (3-5) are interconnected in a network, the trabecular spacing is reduced, and the specific data are shown in table 3.
TABLE 3
TABLE 4
As can be seen from the experimental results shown in fig. 2, tables 3 and 4, the composition of the present invention, calcium + vitamin D + PDX + GOS, with a preferred ratio (PDX: GOS ═ 4: 1), can significantly improve the bone health status of animals in the growth period, including increasing bone calcium content, increasing bone density, increasing number of bone trabeculae, decreasing bone trabecular distance, increasing bone volume fraction, and has significantly better effect than the high calcium dose group, the same calcium + vitamin D group, and the same calcium + vitamin D + PDX + GOS combination (PDX: GOS ═ 1: 1) group.
The foregoing is only a preferred embodiment of the present invention. It will be appreciated that various modifications, combinations, alterations, and substitutions of the details and features of the invention may be made by those skilled in the art without departing from the spirit and nature of the invention. Such modifications, combinations, alterations and substitutions are also to be understood as being included within the scope of the invention as claimed.
Claims (10)
1. A composition for improving bone health, the composition comprising the raw material components: the calcium supplement comprises a calcium source, vitamin D and prebiotics, wherein the prebiotics comprise polydextrose and galactooligosaccharides, and the weight ratio of the polydextrose to the galactooligosaccharides is 3-6: 1; the composition comprises the following nutritional ingredients in parts by weight: 12-66 ten thousand parts of calcium, 1-7 parts of vitamin D, 266-2240 ten thousand parts of polydextrose and 67-560 ten thousand parts of galacto-oligosaccharide.
2. The composition according to claim 1, wherein the polydextrose has an average degree of polymerization of 8-16 and a purity > 90%.
3. A food product comprising the composition of claim 1 or 2.
4. The food product of claim 3, wherein the food product is selected from at least one of dairy, health food, and snack food.
5. Use of the composition of claim 1 or 2 in the preparation of a food product for improving one or more of bone density, bone calcium content and bone microstructure in an animal.
6. The use of claim 5, wherein the bone microstructure is selected from at least one of trabecular number, trabecular separation, and bone volume fraction.
7. Use according to claim 5, wherein the animal is selected from the group consisting of adult-period animals and other animals with insufficient calcium intake during growth phases.
8. The use of claim 5, wherein the animal is a mammal.
9. The use of claim 7, wherein the adult-stage animal is an adult-stage child; the other growth stage calcium deficient animals are humans with calcium deficient intake.
10. Use according to claim 7, wherein the other growth stage calcium deficient animals are elderly populations with calcium deficient intake.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110237626.4A CN112971146B (en) | 2021-03-03 | 2021-03-03 | Composition and food for improving bone health and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110237626.4A CN112971146B (en) | 2021-03-03 | 2021-03-03 | Composition and food for improving bone health and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112971146A CN112971146A (en) | 2021-06-18 |
| CN112971146B true CN112971146B (en) | 2022-03-29 |
Family
ID=76352545
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110237626.4A Active CN112971146B (en) | 2021-03-03 | 2021-03-03 | Composition and food for improving bone health and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112971146B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114451458A (en) * | 2021-10-15 | 2022-05-10 | 东北农业大学 | Children processed cheese beneficial to bone health and height development |
| CN116406706A (en) * | 2022-11-28 | 2023-07-11 | 内蒙古伊利实业集团股份有限公司 | Modulated milk powder for improving absorption capacity and application thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102511720A (en) * | 2011-12-23 | 2012-06-27 | 内蒙古伊利实业集团股份有限公司 | Stachyose infant nourishing cereal and its preparation method |
| CN103561592A (en) * | 2011-03-21 | 2014-02-05 | 雅培制药有限公司 | Methods for improving bone health in infants using prebiotics |
| CN105050591A (en) * | 2013-04-05 | 2015-11-11 | 雀巢产品技术援助有限公司 | Compositions for use in stimulating bone growth |
| CN107080237A (en) * | 2010-11-30 | 2017-08-22 | Mjn 美国控股有限责任公司 | To promote the Infants'feeding scheme stage by stage of healthy development and growth |
| CN109287920A (en) * | 2018-09-14 | 2019-02-01 | 安吉艾格赛思生物科技有限公司 | A kind of solid beverage and preparation method thereof of multicomponent complex and multi-joint probiotics |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8425955B2 (en) * | 2009-02-12 | 2013-04-23 | Mead Johnson Nutrition Company | Nutritional composition with prebiotic component |
-
2021
- 2021-03-03 CN CN202110237626.4A patent/CN112971146B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107080237A (en) * | 2010-11-30 | 2017-08-22 | Mjn 美国控股有限责任公司 | To promote the Infants'feeding scheme stage by stage of healthy development and growth |
| CN103561592A (en) * | 2011-03-21 | 2014-02-05 | 雅培制药有限公司 | Methods for improving bone health in infants using prebiotics |
| CN102511720A (en) * | 2011-12-23 | 2012-06-27 | 内蒙古伊利实业集团股份有限公司 | Stachyose infant nourishing cereal and its preparation method |
| CN105050591A (en) * | 2013-04-05 | 2015-11-11 | 雀巢产品技术援助有限公司 | Compositions for use in stimulating bone growth |
| CN109287920A (en) * | 2018-09-14 | 2019-02-01 | 安吉艾格赛思生物科技有限公司 | A kind of solid beverage and preparation method thereof of multicomponent complex and multi-joint probiotics |
Non-Patent Citations (5)
| Title |
|---|
| Dietary galactooligosaccharides increase calcium absorption in normal and gastrectomized rats;ELISVÂNIA FREITAS DOS SANTOS等;《Revista do Colegio Brasileiro de Cirurgioes》;20111231;第38卷(第3期);第186-190页 * |
| Ingestion of prebiotics prevents gastrectomy-induced iron malabsorption and anemia? Experimental study in rats;Elisvânia Freitas dos SANTOS等;《ABCD.Arquivos Brasileiros de Cirurgia Digestiva》;20111231;第24卷(第1期);第9-14页 * |
| The Importance of Prebiotics in Functional Foods and Clinical Practice;Valéria Maria Caselato de Sousa等;《Food and Nutrition Sciences》;20110430;第133-144页 * |
| The Interplay between Immune System and Microbiota in Osteoporosis;Pietro Locantore等;《Mediators of Inflammation》;20200226;第1-8页 * |
| 低聚果糖与婴幼儿健康关系的研究进展;武薇等;《中国食物与营养》;20200628;第26卷(第06期);第5-9页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112971146A (en) | 2021-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112971146B (en) | Composition and food for improving bone health and application | |
| Glasgow et al. | Rachitic respiratory distress in small preterm infants. | |
| US11185563B2 (en) | Method and composition for preventing, treating or relieving bone diseases | |
| Zeman et al. | Bone mineral density in patients with phenylketonuria | |
| EP2502506A1 (en) | Methods for improving bone health in infants using long chain polyunsaturated fatty acids | |
| EP2502507A1 (en) | Methods for improving bone health in infants using prebiotics | |
| EP2247199A1 (en) | Methods and compositions for the treatment of bone conditions | |
| DK2819528T3 (en) | ENERGY-LIQUID NUTRITIONAL NUTRITIONAL COMPOSITION WITH IMPROVED ORGANOLEPTIC PROPERTIES | |
| Wang et al. | Influence of particle size and calcium source on production performance, egg quality, and bone parameters in laying ducks | |
| US20230218648A1 (en) | Use of human milk oligosaccharides in nutritional compositions for enhancing bone development and/or bone strength | |
| CN112584848A (en) | Probiotic compositions and uses thereof | |
| JP3693359B2 (en) | Bone strengthening promoter | |
| EFSA Panel on Food Additives and Nutrient Sources added to Food (ANS) | Scientific Opinion on re‐evaluation of calcium carbonate (E 170) as a food additive | |
| CN115024361A (en) | Formula milk for improving bone health as well as preparation method and application thereof | |
| JP6265335B2 (en) | Bone density increasing agent, osteoclast activity inhibitor, and bone remodeling improving agent | |
| Chakraborty et al. | Eggshell: An alternative, cheap, bioavailable source of calcium in human diet | |
| WO2023111302A1 (en) | Complex coacervates of lactoferrin and osteopontin | |
| CN1116925A (en) | Cod liver oil emulsion and its preparation | |
| CN114451563A (en) | Composition, application thereof and food | |
| CN114868923A (en) | Nutritional composition, food product comprising the same and use of the nutritional composition | |
| CN108125941A (en) | A kind of application of E-10- hydroxyls -2- decylenic acids in the drug or health products for preparing anti-curing osteoporosis | |
| CN114403235A (en) | Bone-good probiotic formula milk powder for preventing senile osteoporosis | |
| LT4266B (en) | Milk product enriched with ground eggshell | |
| JP6058223B2 (en) | Phosphorus absorption inhibiting composition | |
| JP2010248147A (en) | Anti-mental fatigue agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20210618 Assignee: Inner Mongolia yijiahao cheese Co.,Ltd. Assignor: INNER MONGOLIA YILI INDUSTRIAL GROUP Co.,Ltd. Contract record no.: X2022980005915 Denomination of invention: Composition, food and application for improving bone health Granted publication date: 20220329 License type: Common License Record date: 20220523 |